Post by
Pimpovish on Dec 30, 2020 10:53am
Someone pointed out SVA—Sernova Corp
SVA--$142 million marketcap.
This is a lesser evolved company and its running hot. They have currently enrolled 5 patients for clinical trials. Their tech is based on cellular transplantation.
HEM--post rollback, post financing has a marketcap of $39 million. 10 years of data based on clinicals with a high number of patients and 91 patents around cultured cellular growth and transplantation.
The majority of investors in this stock are longer term and not looking to lock in short term gains.
To be fair, theres nothing wrong in taking profits but like a lot of investors on this one, I'm looking for a homerun.
Comment by
auricgold on Dec 30, 2020 3:42pm
its a no brainer even with a market cap of 50 million.